Key Facts

Invested since 2013
Based in North Rhine-Westphalia

About the company

There are millions of people across the globe suffering from “bone deformities” e.g., limbs or bones of different lengths or scoliosis of their spine. A range of factors can cause these defects: traumatic injury, infections, cancers, and congenital abnormalities. For patients, the deformity may be painful to live with, but the social and psychological stigma can be devastating and can completely wreck their quality of life.

Synoste-ECU

These patients have only a limited range of very painful and inconvenient treatment options – stressful for the patient and their families. For patients with deformed limbs, the most widely used treatment remains limb lengthening with external fixation. While the fixator itself is comparatively cheap, it must be worn for many months, it pierces the patient’s skin and is extremely cumbersome, uncomfortable, and complication prone. The high rate of complications and long sick leaves result in high total treatment costs.

We have used our engineering competencies in the management of smart materials and wireless electronics to create a true disruptive change in treating the above-mentioned patient group. Our first product will be a complete leg lengthening solution. The Synoste Nitinail is an internally implantable device that offers greater patient safety, lengthening control, and convenience; this results in a better patient and cost outcomes. The implantable Synoste Nitinail guarantees patients safer treatment, less infections, and less pain. Synoste means a faster return to work and regaining your quality of life quality.

Do you want to

know more about this company?

Zum Artikel

Kay G. Balster Principal

Kay G. BalsterPrincipal

Synoste in the news

Zum Artikel

News

21. October 2020

Successful exit for High-Tech Gründerfonds and Evonik Venture Capital – Synoste Oy becomes part of Globus Medical

Zum Artikel

News

18. October 2018

SYNOSTE Ltd raises €5.1 million to launch its smart skeletal deformation correction technology

Zum Artikel

News

21. January 2016

Venture Capital: Evonik invests in SYNOSTE, a medical technology start-up in Düsseldorf and Helsinki

Zum Artikel

Press

6. May 2015

Synoste Oy raises € 2.2 M in the first closing of A-round financing to acquire CE-approval for a next generation implant for correcting skeletal deformities

Zum Artikel

Press

14. November 2013

Synoste Oy raises € 2.8 M in financing to Develop Next-Generation implants for correcting skeletal deformities